April 2022 Update: BioGX in silico analysis of SARS-CoV-2 Variants of Concern

BioGX continuously monitors the evolution of COVID-19 variants to ensure our market leading SARS-CoV-2 RT-PCR tests will continue to detect emerging variants without impacting performance.


BioGX has completed in-silico analysis of over 2.5 million SARS-CoV-2 genome sequences available as of March 31, 2022. Sequence analysis compared the available Omicron genomes against the SARS-CoV-2 nucleocapsid (N-gene) and envelope (E-gene) , targeted by BioGX products. In-silico analysis and empirical testing of the Omicron variant confirmed the gene mutations will not affect the performance of the BioGX portfolio of SARS-CoV-2 products.


BioGX portfolio of SARS-CoV-2 products

  1. BioGX Xfree™ COVID-19 Direct RT-PCR – FDA EUA
  2. BD BioGX SARS-CoV-2 Reagents for BD MAX™ System
  3. BioGX SARS-CoV-2 HMP – N1, N2 & RNase P Multiplex
  4. BioGX COVID-19, Flu A, Flu B, RSV RT-PCR for BD MAX™
  5. BioGX SARS-CoV-2 N1, N2, E-gene (RUO)
  6. BioGX SARS-CoV-2 N1, Flu A, Flu B, RSV A/B (RUO)


U.S. CDC and WHO Variants of Concern*  % Clades detected by targets
WHO designation Pango lineage GISAID


Nextstrain clade Spike Protein 

(a.a. changes)

Region Initially Documented (Date) No. Sequences Analyzed 


N1 N2 E
Alpha B.1.1.7


GRY 20I (V1) 69del, 70del, 144del, (E484K**),(S494P**),N501Y, A570D, D614G, P681H, T716I, S982A, D1118H, (K1191N**) United Kingdom (SEP 2020) 428,332


Beta B.1.351



GH/501Y.V2 20H (V2) L18F, D80A, D215G, 241del, 242del, 243del, K417N, E484K, N501Y, D614G, A701V South Africa (MAY 2020) 26,051


Gamma P.1


GR/501Y.V3 20J (V3) 681H,L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I Brazil

(NOV 2020)



Delta B.1.617.2


G/478K.V1 21A, 21I, 21J 417N, T19R, (V70F**), T95I, G142D, E156-, F157-, R158G, (A222V**), (W258L**), (K417N**), L452R, T478K, D614G, P681R, D950N India

(OCT 2020)



Omicron B.1.529


GR/484A 21K, 21L, 21M +R346K Multiple Countries

(NOV 2021)




*Variants of concern being monitored by US CDC and WHO. 

**Present in a subset of sequences.

BA.2 is a sub- lineage of Omicron variant